DanAbdunNabi

President & CEO, Emergent BioSolutions Inc.

Mr. Abdun-Nabi is the President and Chief Executive Officer of Emergent BioSolutions, a NYSE listed global biopharmaceutical company  that pursues the development and commercialization of innovative products to prevent or treat infectious diseases, cancers, and autoimmune disorders. He has held this position since April 2012.  Prior to that, he served as President and Chief Operating Officer (March 2007 to April 2012), as Senior Vice President Corporate Affairs and General Counsel (December 2004 to April 2007), and as Vice President and General Counsel (May 2004 to December 2004) of the company.

 

rbendisPresident & CEO, BioHealth Innovation, Inc.

Mr. Bendis is an entrepreneur, corporate executive, venture capitalist, investment banker, innovation and technology-based economic development leader, international speaker and consultant in the technology and healthcare industries. He currently serves as the founding President and CEO of Innovation America (IA), a national public-private partnership focused on accelerating the growth of innovation economy in America. As one of the most recognized experts in the field of innovation economy, Mr. Bendis has served on numerous distinguished boards and task forces including the White House U.S. Innovation Partnership Advisory Task Force, the Small Business Innovation Research Committee, the National Association of State Venture Funds board; State Science and Technology Institute, and the Ernst and Young Entrepreneurial Institute as a national/regional Judge.

Mr. Bendis has provided global consulting services to over 16 countries and 22 states, several cities and regions, along with international organizations including the United Nations, NATO, UK Trade and Industry, European Commission, French Embassy, the German Marshall Fund, The Canadian Consulate, METI, AKEA, the International Science Parks and Innovation Expert Group and other global entities. Mr. Bendis is a frequent consultant and speaker to 16 International innovation based economic development organizations, as well as over 20 states, regions and cities throughout the U.S. He was voted one of the Top 5 Speakers on innovation economy in 2012.

Senior Director, External Partnerships & Collaborations, MedImmune

Jarrod BorkatJarrod Borkat is a 15-year veteran in the biopharmaceutical industry. He joined MedImmune in 2010, where he currently serves as Senior Director/Head, Global External Partnerships & Collaborations. In this role he is responsible for establishing and overseeing global strategic collaborations with universities, non-profit organizations and government entities, across all the therapeutic areas relevant to MedImmune. His team led the creation of several multi-million dollar collaborations, including one with Johns Hopkins University and one with University of Maryland. Prior to this role, Jarrod led the Portfolio Strategy & Management function for MedImmune, helping the organization optimize its R&D portfolio. Before joining MedImmune, Jarrod worked at Boehringer Ingelheim (BI) Pharmaceuticals, Inc. for 11 years, rising through the ranks in the sales and commercial organization. During his time at BI, he spent two years in Germany, working at their corporate headquarters, leading the global commercial strategy for their CNS franchise. His last position prior to leaving BI was Director of U.S. Marketing, HIV. Jarrod has won multiple awards throughout his career, including being recognized as an industry “Top 25 Direct-to-Consumer Marketer of the Year” in 2007. He is also active in several industry organizations and has served on industry-related panels. In addition to his professional accomplishments, Jarrod serves on the Kentlands Board of Trustees and the Kentlands Community Foundation Board. He also ran a marathon on all 7 continents with his father, making them the first father/son duo to have accomplished this challenging endeavor. Jarrod earned an M.B.A. from Kennesaw State University, with concentrations in finance and marketing, and earned a B.S. in Biology from the University of Georgia.

robertcaret

Chancellor, University System of Maryland

Robert L. Caret joined the University System of Maryland (USM) as chancellor in 2015. During his 20 years of public higher education leadership, Caret has earned respect for his successful work in several areas, including helping to ensure college affordability, academic excellence, and the efficient use of resources. Before joining USM as chancellor, Caret was president of the University of Massachusetts System (UMass) from 2011 until 2015. Prior to joining UMass, Caret was president of Towson University (TU) from 2003 to 2011, where he was instrumental in establishing Towson University in Northeastern Maryland. From 1995 to 2003, Caret served as president of San Jose State University (SJSU).Caret serves on the National Association of System Heads, American Association of State Colleges and Universities, Association of Public and Land-grant Universities, and the Business-Higher Education Forum boards. He also is a member of the National Security Higher Education Advisory Board and the Government University Industry Research Roundtable. Caret also serves on a number of boards in Maryland, including the Greater Baltimore Committee, Economic Alliance of Greater Baltimore, University of Maryland Medical System, College Savings Plans of Maryland, World Trade Center Institute, Maryland Council on Economic Education, BioHealth Innovation, Inc., and the Maryland Economic Development Corporation. In 2016, The Daily Record named him among its 2016 list of Influential Marylanders.

Group Vice President, Healthcare Banking, M&T BankChristopher Callaghan

Mr. Callaghan manages M&T’s Healthcare Banking Group, providing sales advisory, credit oversight and industry training to the team. Christopher joined M&T Bank in 1994. He has held several positions in the Corporate Banking and Institutional Investment Management Divisions at M&T, including 15 years in the Healthcare Banking Group. M&T’s Healthcare Banking Group is a Specialized Industry Group that provides Commercial Lending, Investment Banking, Treasury Management and other Financial Services to Health Systems, Hospitals, Skill Nursing Facilities and Senior Living Communities. Christopher received a Bachelor of Arts degree in Economics from Saint Michael’s College in Winooski, Vermont and a Master’s of Science in Finance from The Johns Hopkins University. He is a member of the Board of Directors of Evergreen Healthcare Cooperative, the Board of Visitors of the University of Maryland School of Nursing and is active in several healthcare industry groups.

President and CEO, Noble Life Sciences

kenneth carter

Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During this time, Avalon developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune.

Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he worked for several years and played a role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter has served on the boards of directors for multiple biotechnology industry organizations including the Maryland Health Care Product Development Corporation and the National BIO Industry Organization. He also served recently as a special advisor to the Maryland Governor's Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.

Founder and CEO, Immunomic Therapeutics, Inc.

Dr. William Hearl is the founder of Immunomic Therapeutics, Inc. and is an experienced and successful life science businessman and entrepreneur. Dr. Hearl is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities. Recently, Dr. Hearl led ITI into a significant licensing agreement with Astellas Pharma Inc., to explore the use of LAMP-vax, a next-generation immunotherapy platform, for use to prevent and treat allergic diseases. ITI believes that LAMP-based nucleic acid immunotherapy may have the potential to broaden the current use of cancer immunotherapy.   In fact, preclinical data is currently being developed to explore how LAMP nucleic acid constructs could both amplify and activate the immune response in highly immunogenic tumor types and also be used to create robust immune responses to tumor types that otherwise do not provoke an immune response.

The advent of LAMP technology came from Dr. Hearl’s work with Dr. Tom August of Capital Genomix, Inc. and Johns Hopkins University. From that collaboration, ITI began operations in 2006. Dr. Hearl’s extensive experience in intellectual property management and business development led to the rewarding sub-license of the LAMP technology to Geron Corporation within 30 days of initiating operations and subsequent license agreements, valued at over $300 million, in 2015 with Japan-based Astellas for next generation allergy vaccines based on the LAMP platform.

Dr. Hearl is also the founder of Capital Genomix, Inc. (CGI), a Maryland-based biomarker and drug discovery Company and served as its first chief executive officer from inception in 2000 to late 2002 when he assumed the role of chief scientific officer. Dr. Hearl raised seed funds and series A & B funding for CGI (approximately $5 million in cash/debt). He also acquired the Dynex Technologies division of Thermo Scientific in a leveraged acquisition deal. Dynex was subsequently divested and yielded a remarkable tenfold return to the Company.

Dr. Hearl is also responsible for the acquisition and development of the core technologies of Capital Genomix: GeneSystem320™ was licensed exclusively from MD Anderson Cancer Center and the ImmunoMouse™ was invented by Dr. Hearl. Dr. Hearl also has an established record of scientific productivity over his 20 years of work in the biotech industry. He started his career as a bench scientist at Electro-Nucleonics, Inc. and developed blood based diagnostics for HIV, HTLV-I and Hepatitis C. He later worked at Life Technologies Incorporated and directed the immunodetection group. Under Dr. Hearl’s direction, the lab developed a number of innovative antibody-based detection kits and reagents. He moved into scientific management when he became the director of research and development at Kirkegaard & Perry Laboratories, Inc. in 1994.

Dr. Hearl earned his Ph.D. in biochemistry from the University of Tennessee and B.S. from East Tennessee State University.

rdaniels

President, Johns Hopkins University

Ronald J. Daniels became the 14th president of The Johns Hopkins University in March 2009. A law and economics scholar, he holds an appointment as professor in the Department of Political Science at Johns Hopkins. Prior to his appointment, he served as provost of the University of Pennsylvania, and dean and James M. Tory Professor of Law at the University of Toronto Faculty of Law. Daniels' own research focuses on the intersections of law, economics, development and public policy, in such areas as corporate and securities law, social and economic regulation and the role of law and legal institutions in promoting third world development. He is the author or co-author of dozens of scholarly articles, and the author or editor of seven books.

Daniels currently sits on the boards of the East Baltimore Development Inc., the Baltimore Community Foundation, the Goldseker Foundation, the Maryland Chamber of Commerce, the Governor's International Advisory Council, and the Asia Pacific Rim Universities World Institute. He is serving as a member of the Association of American Universities-Association of Leading Russian Universities steering committee to help guide collaborations between member universities. He is also engaged in the Center for Health Policy and Healthcare Transformation at Johns Hopkins. In 2009, he was elected a fellow of the American Academy of Arts and Sciences.

jens eckstein

President, SR One

Dr. Eckstein is the President of SR One which is the corporate venture capital arm of GlaxoSmithKline. He came to GlaxoSmithKline from TVM Capital where he was a Venture Partner, Entrepreneur-in Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He was a member of the Board of Directors for CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an Advisor to Sirtris Pharmaceuticals.

 

David M. Gillece

Regional Managing Principal, Cassidy Turley

David Gillece oversees Cassidy Turley’s offices in Baltimore, MD. He also serves on the Board of Cassidy Turley. David has a strong background in Corporate Services, having served in senior positions with major accounts. He maintains a strong Advisory/ Tenant Representation practice. Major clients have included Legg Mason, Under Armour, Travelers, The Johns Hopkins University and RTKL.

David chairs Cassidy Turley’s Life Science practice group. He served as Chairman of the Board of the State of Maryland’s Enterprise Investment Fund, an early stage equity fund focused on young technology companies. He has also served as consultant to the University of Maryland Baltimore County in the development of its university research park and on the listing team at the Johns Hopkins and University of Maryland bioparks.

Prior to joining Cassidy Turley, Mr. Gillece served as President and CEO of the Baltimore Development Corporation, Baltimore City’s economic development agency. 

rick iveyWW Vice President Research & Development, BD Diagnostics

Rick is the overall R&D Leader for the Diagnostic Systems Research and Development Function. Rick works closely with the business leaders to drive new growth opportunities via technology and product development, collaborative partnerships, technology functional excellence, platform management, technology planning, and hiring of talent to meet our strategic goals. Diagnostic Systems comprises several BD Market Segment Areas including Molecular Diagnostics (BD Max and BD Viper), Infection Prevention and Management (includes Microbiology, POC and Industrial platforms), and Women's Health. The R&D team is comprised of a strong Systems Engineering function with equally strong Microbiology, Molecular, Chemistry, Immuno and Cytology teams located in multiple sites in North America. Rick has received multiple patents in the field of rapid Sepsis Detection, a strong area of personal interest. Rick received his B.S. in Mechanical Engineering from Virginia Tech and a Masters in Engineering Science and Administration from The George Washington University.

 

dave-lemusCEO, Sigma-Tau Pharmaceuticals, Inc.

Dave Lemus heads Sigma Tau Pharmaceuticals activities in North America, based in Gaithersburg, MD, which conducts the R&D, global manufacturing and sales/ commercialization within the Americas, of the company’s Rx (rare disease) and OTC therapeutics portfolio. Dave also currently serves as a non-executive board member of various European and North American companies, including board chair of Proteros GmbH, a leading structural biology focused company co- founded by Nobel prize-winner Dr. Robert Huber. Additionally he serves as a non-executive board member of Medigene AG, a publically listed biotechnology company in Germany, as well as Axela Inc., a private diagnostics company based in Toronto, Canada.

dougliuSenior Vice President of Global Operations, QIAGEN

Douglas Liu has a twenty five year record of international success in operations, strategic planning and Research & Development in molecular diagnostics, immunodiagnostics and other healthcare market segments. 

Douglas Liu is the Senior Vice President of Global Operations, a member of the Executive Committee and the senior QIAGEN Executive assigned in North America.  As the head of Global Operations, Douglas manages Manufacturing, Quality Control, Quality Assurance, Regulatory Affairs, and Supply Chain worldwide.   He is also the Chairman of the America Management Council at the QIAGEN Germantown/Gaithersburg/Frederick office where he provides leadership and guidance to all of the US subsidiaries, projects, and employees.  Under his management and commitment to success, QIAGEN North America has achieved and contributed to multiple successful projects and its growth, including the Germantown campus expansion.

Before joining QIAGEN, Douglas worked for Bayer Healthcare as Head of Operations for nucleic acid diagnostics in the US, and in strategic planning and consulting at Bayer AG in Leverkusen.  Prior to these positions, Douglas also worked at Abbott Labs and Chiron Diagnostics.

Douglas received his MBA from Boston University and his Bachelor Science degree from University of Illinois, Urbana

Douglas lived and worked in Germany for five years.  In 2007, Douglas and his family relocated back to United States. He has served in several local advisory boards since returning to the US including the Governor International Advisory Council & the MD Bio Tech Council of Maryland.

juan-carlosHead of Academic Relations and Collaborations, Roche

Juan Carlos López was born in Oaxaca, México, in 1967. He obtained his first degree on Biomedical Research at the Universidad Nacional Autónoma de México, majoring in neuroscience. Juan Carlos got his Ph.D. degree from Columbia University (New York) in the laboratory of Eric Kandel, studying synaptic plasticity in neuronal cultures. He then carried out postdoctoral work at the Instituto Cajal (Madrid), studying presynaptic mechanisms of transmitter release. During this period, Juan Carlos wrote a book on the neurobiology of memory (“El Telar de la Memoria”, Algar Editorial), with which he won the IV European Award of Scientific Dissemination in 1998. Two years later, Juan Carlos left experimental research to become Editor of Nature Reviews Neuroscience in London. In January 2004, he returned to New York to become the Chief Editor of Nature Medicine. In February 2014, Juan Carlos left the publishing industry to become Head of Academic Relations and Collaborations at Hoffmann-La Roche. In this role, he and his team are charged with fostering interactions of his company with academic institutions worldwide with the aim of promoting the advance of translational research and the discovery of new medicines. Juan Carlos has also served as a member of the Scientific Advisory Board and of the Board of Directors of Noscira, a Spanish biotechnology company interested in neurodegeneration. He is member of the Board of Directors of the Eureka Institute, an international initiative that aims to promote translational research by fostering the education of MDs and PhDs interested in bridging the gap between bench and bedside, and of the Board of Directors of Keystone Symposia, non-profit organization devoted to the advancement of science through its prestigious series of conferences.

joel-marcusCEO & Founder, Alexandria Real Estate Equities, Inc.

Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), the largest and leading REIT uniquely focused on collaborative science and technology campuses in urban innovation clusters. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with a business plan and $19 million of seed capital, and has led its growth into a publicly traded, investment-grade REIT with a total market capitalization of approximately $9 billion and dominant market presence in leading AAA locations, including Greater Boston, the San Francisco Bay Area, New York City, Seattle, San Diego, Maryland, and Research Triangle Park. Mr. Marcus founded and leads Alexandria Venture Investments, the Company’s strategic venture arm, which has made over 200 investments in biopharmaceuticals, diagnostics, research tools, technology platforms, medical devices, digital health, and other cutting-edge technologies.

lilyqi

Assistant Chief Administrative Officer, Montgomery County

Lily Qi is Assistant Chief Administrative Officer for economic and workforce development in Montgomery County. She has served County Executive Ike Leggett for the eight years in various capacities and overseen strategic initiatives including privatizing economic development functions, establishing BioHealth Innovation, Inc. to advance biomedical research commercialization, developing global partnerships, improving nighttime economy, and developing the Comprehensive Economic Strategy.

Lily joined Montgomery County after serving as Vice President of Business Development and Marketing for the Washington, DC Economic Partnership and spokesperson for the DC Department of Insurance, Securities and Banking.

An immigrant who grew up in Shanghai, China, Lily is also a writer, speaker and trainer on cultural competency and immigrant integration issues. She was featured in the Washington Business Journal, Bethesda Magazine, China Daily, and Asian Fortune for her professional accomplishments and community leadership, which includes serving as trustee of the Suburban Hospital of Johns Hopkins Medicine and board member of VisArts and immediate past chair of the Maryland Governor’s Commission on Asian American Affairs.

beth-meagherDirector, Deloitte Consulting LLP

Ms. Meagher has over 19 years of experience leading strategic initiatives for clients in commercial, government, and non-profit sectors. Currently, she is leading Deloitte’s Federal Strategy Practice with over 90 consultants and she started and leads Deloitte’s Translational Science Team with over 35 practitioners and is the Federal Life Sciences Market Lead and Federal Health Analytics Lead. She is leading efforts to assist clients in analytics efforts, growth strategies, public private partnerships, strategic planning, program evaluation, stakeholder management, change management, executive leadership, and communication strategies. Ms. Meagher is an expert at Go To Market strategy development, routinely developing high performing teams that outperform the market. She has C-suite relationships across the Federal, Commercial, and Non Profit markets. She holds a MA in Organization Effectiveness and a BA in Communication Studies and Entrepreneurial Studies.

charles-mortonPartner, Venable

Chuck Morton, repeatedly ranked as one of the top M&A lawyers in the country, co-chairs Venable's Corporate Practice Group, splitting his time between Venable's Washington and Baltimore offices. He has a national practice, solving complex problems faced by lenders, investors, and entrepreneurs as they create, build, and buy or sell businesses. He routinely advises on mergers and acquisitions and financings, including every flavor of equity investment. He regularly acts on behalf of private equity groups and banks.

davidmott

General Partner, New Enterprise Associates, NEA

David M. Mott joined NEA in September 2008 as a General Partner focused on biopharmaceutical investments. Prior to joining NEA, he was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Dave founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees.

Prior to joining MedImmune, Dave was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. At Smith Barney, his activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies. Dave is currently Chairman of 3-V Biosciences, TESARO, and Zyngenia and is a director of Ardelyx, Epizyme, and Omthera. He also serves on the Governing Board of St. Albans School.

tom-sadowskiPresident and CEO, Economic Alliance of Greater Baltimore

The Economic Alliance is a partnership of business, government and higher education leaders marketing Greater Baltimore as a world-class region in which to work, learn, live and invest.

Tom joined the Alliance in Jan 2006 to manage the Region's response to the 2005 DOD Base Realignment and Closure (BRAC) initiative. Since, he has led strategic marketing efforts reaching more than 20,000 defense/IT, cyber and bio-health industry execs; executed sales missions to Austin, NYC, Palo Alto and San Francisco; increased business retention, development and public/private partnership activity; and published a new series of regional, industry-specific market reports. His work has also helped foster new regional and state-wide initiatives in the areas of tech transfer, commercialization and entrepreneurship, working with Johns Hopkins, the University of Maryland and federal customers such as NIH, APG and US Cyber Command.

In his 24 year career, he led the '05 BRAC win for Aberdeen Proving Ground; brokered major development and HQ/campus projects for Battelle, Bank of America, SafeNet, T. Rowe Price and the US Centers for Medicare and Medicaid Services (CMS). His clients to date have included: ADP, Booz Allen, CACI, Clorox, FLIR, Millennial Media, Morgan Stanley, Transamerica and Under Armour to name a few.

Overall, his projects have exceeded $10 billion in value, resulting in approximately 60,000 jobs. His efforts have been recognized by local media, most recently named as an "Influential Marylander" and one of "Maryland Most Admired CEOs."

He is a proud husband, father of four boys and graduate of UMBC and Leadership Maryland. A 10+ year cancer survivor, Tom is also an advocate for enhanced awareness, research and family services.

 

mike-gillSecretary of Commerce, Maryland Department of Commerce

Secretary Mike Gill is a business leader with four decades of experience as an entrepreneur, a technology executive, an investment banker, and a public servant. He was tapped by Governor Larry Hogan to lead the Maryland Department of Business and Economic Development (DBED) in January 2015. Prior to his appointment, Mike Gill led Evergreen Advisors, an investment bank, as chairman and principal. Previously, Gill founded Hoyt Capital, an investment and advisory firm serving startups and growth companies. Mr. Gill was also a founder First Page, which was acquired by Metrocall; served as chairman of Curtis Engine, a Baltimore power generator company; and was chairman of Bluefire Security Technologies, a mobile cybersecurity developer, from 2006 to 2008. In 1984, Gill founded AMERICOM, a Baltimore-based provider of cellular products and services to businesses in the area. Under Gill’s leadership, AMERICOM expanded nationwide with more than 1,200 team members. In 2000, it was acquired by Solectron. He started his career with IBM and held a number of positions in sales and marketing. He then became Director of Data Systems in the mid-Atlantic region for Ernst & Young. Gill served on the University System of Maryland Board of Regents from 2004 to 2009, heading the audit committee and technology transfer and commercialization workgroup. His past and present board memberships also include the Calvert Hall Board of Trustees, Baltimore County Economic Development Commission, St. Joseph's Medical Center, Bay National Bank, and Towson University of Board of Visitors. He is also a member of the President's Advisory Board at Clemson University. Gill earned his B.S. in business administration from Towson University in 1974 after first attending Clemson University on a baseball scholarship. He was awarded an honorary Doctor of Humane Letters degree by Towson University in 1996.